{"id":"fluorouracil-implants","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Mucositis"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Anemia"},{"rate":"1-5%","effect":"Thrombocytopenia"},{"rate":"1-5%","effect":"Infection"},{"rate":"1-5%","effect":"Pain"}]},"_chembl":{"chemblId":"CHEMBL185","moleculeType":"Small molecule","molecularWeight":"130.08"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, leading to the depletion of thymidine triphosphate and the disruption of DNA synthesis and function. This results in the inhibition of cancer cell growth and proliferation.","oneSentence":"Fluorouracil implants work by releasing fluorouracil, a thymidylate synthase inhibitor, which interferes with DNA synthesis and function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:00.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of resectable rectal cancer"}]},"trialDetails":[{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT07254091","phase":"EARLY_PHASE1","title":"Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2026-01-30","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT05466799","phase":"PHASE2","title":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoSil Medical Limited","startDate":"2023-04-26","conditions":"Locally Advanced Pancreatic Cancer","enrollment":88},{"nctId":"NCT07353827","phase":"PHASE2","title":"FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy","enrollment":36},{"nctId":"NCT03366155","phase":"PHASE2","title":"Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-24","conditions":"Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma","enrollment":24},{"nctId":"NCT06988852","phase":"PHASE2","title":"FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-05-01","conditions":"Colorectal Liver Metastasis (CRLM)","enrollment":300},{"nctId":"NCT05316142","phase":"NA","title":"Effect of Subconjunctival 5-fluorouracil on the Outcome of Ahmed Valve in Neovascular Glaucoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Iran University of Medical Sciences","startDate":"2024-05-01","conditions":"Neovascular Glaucoma","enrollment":70},{"nctId":"NCT04251715","phase":"PHASE2","title":"mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-04-28","conditions":"Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","enrollment":5},{"nctId":"NCT00059930","phase":"PHASE1","title":"Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":38},{"nctId":"NCT06278454","phase":"PHASE1","title":"Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)","status":"RECRUITING","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2024-01-09","conditions":"Unresectable Pancreatic Cancer","enrollment":58},{"nctId":"NCT04034251","phase":"PHASE2","title":"Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-09","conditions":"Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction","enrollment":12},{"nctId":"NCT03839823","phase":"PHASE2","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-25","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT00309478","phase":"PHASE3","title":"Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"1990-12","conditions":"Early-stage Breast Cancer","enrollment":1099},{"nctId":"NCT04217954","phase":"PHASE2","title":"HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC","status":"COMPLETED","sponsor":"Peking University","startDate":"2020-07-28","conditions":"Advanced Biliary Tract Cancer","enrollment":32},{"nctId":"NCT02972541","phase":"NA","title":"Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2016-09-30","conditions":"Colorectal Cancer, Neoadjuvant Chemotherapy, Stent","enrollment":248},{"nctId":"NCT00276744","phase":"PHASE2","title":"Individualized Drug Treatment for Treating Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-10","conditions":"Pancreatic Cancer","enrollment":249},{"nctId":"NCT02967887","phase":"PHASE2","title":"Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC","status":"UNKNOWN","sponsor":"CbsBioscience","startDate":"2016-11","conditions":"Hepatocellular Carcinoma Non-Resectable","enrollment":96},{"nctId":"NCT02989207","phase":"NA","title":"Surgical Approaches in Treating Uncontrolled Glaucoma in Black African and African-Caribbeans","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2016-08","conditions":"Primary Open Angle Glaucoma","enrollment":60},{"nctId":"NCT02884128","phase":"PHASE1","title":"A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors","status":"COMPLETED","sponsor":"PharmaEngine","startDate":"2006-01","conditions":"Solid Tumor","enrollment":16},{"nctId":"NCT00817895","phase":"NA","title":"Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence","status":"COMPLETED","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2008-12","conditions":"Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT02423226","phase":"PHASE2","title":"Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer","status":"COMPLETED","sponsor":"The First People's Hospital of Changzhou","startDate":"2008-10","conditions":"Rectum Cancer","enrollment":56},{"nctId":"NCT02269904","phase":"PHASE2","title":"Fluorouracil Implants Used for Intraperitoneal Chemotherapy During Operation for Treatment of Phase III Gastric Cancer.","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2014-04","conditions":"DSF","enrollment":120},{"nctId":"NCT00002793","phase":"PHASE3","title":"Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer","status":"UNKNOWN","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"1991-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":336},{"nctId":"NCT01214343","phase":"PHASE3","title":"Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC","status":"UNKNOWN","sponsor":"Ministry of Health, Labour and Welfare, Japan","startDate":"2010-10","conditions":"Advanced Hepatocellular Carcinoma, Carcinoma, Carcinoma, Hepatocellular","enrollment":190},{"nctId":"NCT01317069","phase":"PHASE2","title":"A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2010-06","conditions":"Gallbladder Cancer, Bile Duct Cancer","enrollment":100},{"nctId":"NCT00933816","phase":"PHASE1, PHASE2","title":"Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy","status":"COMPLETED","sponsor":"Kindai University","startDate":"2009-07","conditions":"Hepatocellular Carcinoma","enrollment":37},{"nctId":"NCT01055743","phase":"PHASE2","title":"The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2009-08","conditions":"Early Stage Hepatocellular Carcinoma","enrollment":250},{"nctId":"NCT01033578","phase":"NA","title":"Efficacy of Postoperative Adjuvant Treatments for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis","status":"UNKNOWN","sponsor":"Fudan University","startDate":"1999-10","conditions":"Hepatocellular Carcinoma","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Fluorouracil Implants","genericName":"Fluorouracil Implants","companyName":"Jiangsu Simcere Pharmaceutical Co., Ltd.","companyId":"jiangsu-simcere-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluorouracil implants work by releasing fluorouracil, a thymidylate synthase inhibitor, which interferes with DNA synthesis and function. Used for Adjuvant treatment of resectable rectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}